Manhattan, New York Clinical Trials

A listing of Manhattan, New York clinical trials actively recruiting patient volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 420 clinical trials
Multi-center Open-label Phase 1b Study in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)

Primary Objectives: To evaluate the safety and tolerability of isatuximab administered subcutaneously (SC) versus intravenously (IV) To evaluate the pharmacokinetics (PK) of SC and IV isatuximab Secondary Objectives: To estimate absolute bioavailability of SC and IV isatuximab To measure receptor occupancy (RO) after isatuximab SC versus IV administration To assess …

refractory multiple myeloma
hydrochloride salt
hepatitis
antibiotics
hepatitis b surface antigen
Investigational Site Number 8400006
 (8.2 away) Contact site
  • 0 views
  • 24 Nov, 2025
  • +13 other locations
Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 12 Years With Hemophilia A or B

Primary Objective: To confirm appropriate dose levels of fitusiran when administered to male pediatric participants (ages 1 to <12 years of age) with severe hemophilia A or B Secondary Objective: To characterize the safety and tolerability To characterize the pharmacokinetics (PK)

fitusiran
antihemophilic factor
haemophilia a
factor ix
hemophilia
Investigational Site Number 8400008
 (8.2 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +10 other locations
Study of Lademirsen (SAR339375) in Patients With Alport Syndrome

Primary Objectives: To assess the efficacy of lademirsen (SAR339375) in reducing the decline in renal function To assess the safety and tolerability of lademirsen (SAR339375) in subjects with Alport syndrome Secondary Objectives: To assess plasma pharmacokinetic (PK) parameters of the parent compound and its metabolites To assess the potential formation …

Columbia University Medical Center_Investigational Site Number :8400004
 (4.2 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +22 other locations
Study of Lademirsen (SAR339375) in Patients With Alport Syndrome  

Primary Objectives: To assess the efficacy of lademirsen (SAR339375) in reducing the decline in renal function To assess the safety and tolerability of lademirsen (SAR339375) in subjects with Alport syndrome Secondary Objectives: To assess plasma pharmacokinetic (PK) parameters of the parent compound and its metabolites To assess the potential formation …

Columbia University Medical Center_Investigational Site Number :8400004
 (4.2 away)
  • 0 views
  • 01 Dec, 2025
  • +19 other locations
UAT Study

Bowen Test Study Overview

Formal Test Site - NY
 (2.3 away) Contact site
  • 0 views
  • 09 May, 2025
  • +7 other locations
None

Memorial Sloan Kettering Cancer Center
 (1.4 away) Contact site
  • 0 views
  • 19 May, 2025
  • +19 other locations
A Study to Evaluate the Efficacy and Safety of Frexalimab, SAR442970, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease (RESULT)

This is a parallel, Phase 2a, double-blind, 6-arm study for the treatment of primary focal segmental glomerulosclerosis (FSGS) or primary minimal change disease (MCD).The purpose of this study is to measure the change in proteinuria and its impact on the rates of remission of nephrotic syndrome with frexalimab, SAR442970, or …

Investigational Site Number : 8400001
 (4.2 away) Contact site
  • 0 views
  • 20 Jun, 2025
  • +24 other locations
Very Early Intensive Treatment of Infants Living With HIV to Achieve HIV Remission - Josh McVoy  

The study will explore the effects of early intensive antiretroviral therapy (ART) with or without a broadly neutralizing antibody (bNAb) on achieving HIV remission (HIV RNA below the limit of detection of the assay) among infants living with HIV.

12001, Malawi Clinical Research Site
 (7.1 away)
  • 0 views
  • 24 Apr, 2026
  • +1 other locations
A Phase 3 Study to Evaluate Efficacy and Safety of AL001 in Frontotemporal Dementia (INFRONT-3)

A phase 3 double blind, placebo controlled study evaluating the efficacy and safety of AL001 in participants at risk for or with frontotemporal dementia due to heterozygous mutations in the progranulin gene.

aphasia
progranulin
pick's disease
dementia
Irving Institute for Clinical and Translational Research
 (4.2 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +46 other locations
A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine

The reason for this study is to see if lasmiditan is safe and effective in children aged 6 to 17 with migraine. The study will last up to 20 weeks and may include up to 4 visits.

treatment regimen
lasmiditan
migraine
headache
ly573144
Columbia University
 (4.2 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +162 other locations